Investigational drug · Phase 2
HRS-6208
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Unresectable or Metastatic Breast Cancer of Adults, Prostate Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "HRS-6208"
First trial start
2024
Sep 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-6208", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Unresectable or Metastatic Breast Cancer of Adults
- Prostate Cancer
Approved drugs for the same conditions: Breast cancer · Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-6208" as an intervention, largest first.
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06727812 · 206 participants (planned) · Start Dec 17, 2024 · Primary completion Aug 2027
Drug: HRS-6208 · For: Solid Tumors
Sites: Nanjing, China; Chengdu, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07389733 · 180 participants (planned) · Start Mar 27, 2026 · Primary completion Dec 2028
Drug: HRS-6208 Capsule; HRS-6209 Capsule and 3 more · For: Advanced Unresectable or Metastatic Breast Cancer of Adults
Sites: Dalian, China; Chengdu, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06568094 · 100 participants (planned) · Start Sep 25, 2024 · Primary completion Dec 2026
Drug: HRS-5041 tablets; Abiraterone Acetate tablets(II) and 6 more · For: Prostate Cancer
Sites: Harbin, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Unresectable or Metastatic Breast Cancer of Adults
- HRS-6209Phase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Breast Cancer, Advanced Unresectable or Metastatic Breast Cancer of Adults
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.